Alzheimer's-slowing drug labelled historic
Lecanemab, a drug by Eisai and Biogen, slows Alzheimer's progression by 27% in early stages, targeting toxic beta-amyloid proteins. Despite side effects like brain swelling, it's hailed as a historic breakthrough, offering hope for meaningful cognitive impact. Full trial details await, with regulatory approval sought in the US, Europe, and Japan.
Reference News
Lecanemab, targeting Alzheimer's by removing toxic beta-amyloid proteins, showed a 27% slower cognitive decline in 1,795 early-stage patients over 18 months, despite side-effects like brain swelling and headaches. It's ineffective for other dementias.
Biogen and Eisai's Alzheimer's drug, lecanemab, showed a 27% reduction in cognitive decline in a large trial, offering hope after previous failures. This marks a potential turnaround for Biogen, following the commercial failure of Aduhelm.
Lecanemab, a drug by Eisai and Biogen, slows Alzheimer's progression by 27% in early stages, targeting toxic beta-amyloid proteins. Despite side effects like brain swelling, it's hailed as a historic breakthrough, offering hope for meaningful cognitive impact. Full trial details await, with regulatory approval sought in the US, Europe, and Japan.